Suven Pharma - Cohance Lifesciences Share Price

Share Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

MF Ownership

• ICICI Pru Pharma Healthcare and Diagnostics (P.H.D) Direct-G

  Equity: Sectoral-Pharma

  4

  • 295.82

    Amount Invested (in Cr.)

  • 4.43572295%

    % of AUM

  • -7.67

    % Change (MoM basis)

• HDFC Balanced Advantage Direct-G

  Hybrid: Dynamic Asset Allocation

  5

  • 200.24

    Amount Invested (in Cr.)

  • 0.19%

    % of AUM

  • 0.00

    % Change (MoM basis)

• Invesco India Contra Direct-G

  Equity: Value Oriented

  3

  • 193.98

    Amount Invested (in Cr.)

  • 1%

    % of AUM

  • 11.55

    % Change (MoM basis)

Corporate Actions

About Suven Pharma

Cohance Lifesciences Ltd., incorporated in the year 2018, is a Small Cap company (having a market cap of Rs 16,333.70 Crore) operating in Pharmaceuticals sector. Cohance Lifesciences Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Sale of services and Scrap for the year ending 31-Mar-2025.For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 617.28 Crore, up 12.09 % from last quarter Total Income of Rs 550.71 Crore and up 49.61 % from last year same quarter Total Income of Rs 412.59 Crore. Company has reported net profit after tax of Rs 8.31 Crore in latest quarter.The company’s top management includes Mr.Vivek Sharma, Dr.V Prasada Raju, Dr.Sudhir Kumar Singh, Mr.Pankaj Patwari, Ms.Shweta Jalan, Mr.Vinod Padikkal, Mr.Jai Shankar Krishnan, Mr.K G Ananthakrishnan, Ms.Matangi Gowrishankar, Mr.U B Pravin Rao, Mr.Vinod Rao, Mr.Himanshu Agarwal, Mr.Kundan Kumar Jha. Company has Karvy & Co. as its auditors. As on 31-03-2026, the company has a total of 38.26 Crore shares outstanding.Suven Pharma Share Price Today is Rs. 426.95. On previous day, the Suven Pharma Share Price (NSE) closed at Rs. 423.45, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 57.49% of the stake in Suven Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Suven Pharma stocks was 5.59% as compared to 6.01% in Dec 2025 with decrease of 0.42%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 21.79% as compared to 21.57% in Dec 2025 with increase of 0.22%. Out of the total DII holdings in Suven Pharma shares 18.57% was held by mutual funds. The rest including public held is 15.13%. Suven Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Suven Pharma Dividend: Ever since 2018, Suven Pharma dividends has been paid out around 8 times. As on 12 Jun, 2026, 03:59 PM IST, The overall dividend yield for Suven Pharma stands at 0.0%. The last dividend paid was on September 9, 2022 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 4.68.

Suven Pharma Bonus: The most recent bonus issue had been in year September 25, 2020 around 5 years ago at 1 : 1 ratio. The first bonus issue was announced in Aug 2020.

Stock Forecast:
After showing 617.28 Cr. of sales and 12.09% of quarterly net profit, there have been multiple ups and downs in the Suven Pharma stock prices in the past few weeks. For example, Suven Pharma stock price on 5th of June 2026 was around Rs. 431.1. Suven Pharma share price now stands at an average of Rs. 426.95. Judging by last week's performance, stock is in down trend.

Suven Pharma has a median target price of Rs. 530.14 in 12 months by 7 analysts. They have provided a high estimate of Rs. 1150.0 and low estimate of Rs. 300.0 for Suven Pharma share.

Historical Prices and Performance:
Suven Pharma,incorporated in 2018 is a Mid Cap company (with a market cap of Rs. 16333.7) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Suven Pharma stock was 4.58%, 15.78%, 14.64%, 23.7% and 29.71% respectively.
The Suven Pharma share gave a 3 year return of -10.13% as compared to Nifty 50 which gave a return of 26.99%.
Suven Pharma announced 100.0% final dividend on September 9, 2022.

Key Metrics:
PE Ratio of Suven Pharma is 91.13
Prices/Sales Ratio of Suven Pharma is 5.09
Price/Book Ratio of Suven Pharma is 4.05

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Suven Pharma,major competitors and peers include Laurus Labs, Biocon, Ipca Labs and Ajanta Pharma. As of Dec 2025, the dividend yield of Suven Pharma stands at 0.0% while Laurus Labs, Biocon, Ipca Labs and Ajanta Pharma stand at 0.14%, 0.12%, 0.38% and 0.89% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 91.13 and 4.05 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 8, Three months ago this number stood at 8. Out of total, 1 analyst have a'Strong Buy' reco, 2 analyst have a'Buy' reco, 1 analyst have a'Hold' reco, 2 analyst have a'Sell' reco.

Mean recommendations by 8 analyst stand at'Buy'.

Leadership of Suven Pharma :
Himanshu Agarwal is Chief Financial Officer
Sudhir Kumar Singh is Chief Executive Officer
Gaurav Bahadur is Chief Human Resource Officer
Kundan Kumar Jha is Head - Legal & Co. Secretary
Vivek Sharma is Executive Chairman
V Prasada Raju is Managing Director
Pankaj Patwari is Non Executive Director
Shweta Jalan is Non Executive Director
Vinod Padikkal is Non Executive Director
Vinod Rao is Independent Director
K G Ananthakrishnan is Independent Director
U B Pravin Rao is Independent Director
Matangi Gowrishankar is Independent Director
Jai Shankar Krishnan is Independent Director


Show More